|
Volumn 47, Issue 9, 2008, Pages 1438-
|
Comment on: Use of parenteral methotrexate significantly reduces the need for biological therapy
|
Author keywords
[No Author keywords available]
|
Indexed keywords
C REACTIVE PROTEIN;
METHOTREXATE;
TUMOR NECROSIS FACTOR ALPHA INHIBITOR;
ANTIRHEUMATIC AGENT;
ARTHRALGIA;
BIOLOGICAL THERAPY;
CLINICAL TRIAL;
DISEASE ACTIVITY;
DRUG ADMINISTRATION ROUTE;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG TOLERABILITY;
DRUG TOLERANCE;
DRUG TREATMENT FAILURE;
DRUG WITHDRAWAL;
HUMAN;
INJECTION SITE REACTION;
JOINT SWELLING;
LEUKOPENIA;
NAUSEA;
NOTE;
PATIENT COMPLIANCE;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SCORING SYSTEM;
TREATMENT DURATION;
FEMALE;
MALE;
PROSPECTIVE STUDY;
SUBCUTANEOUS DRUG ADMINISTRATION;
TREATMENT OUTCOME;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
FEMALE;
HUMANS;
INJECTIONS, SUBCUTANEOUS;
MALE;
METHOTREXATE;
PROSPECTIVE STUDIES;
TREATMENT OUTCOME;
|
EID: 50949123940
PISSN: 14620324
EISSN: 14620332
Source Type: Journal
DOI: 10.1093/rheumatology/ken250 Document Type: Note |
Times cited : (4)
|
References (3)
|